Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Rajamuthiah, Rajmohan ^a,b   Fuchs, Beth Burgwyn ^a   Conery, Annie L ^b   Kim, Wooseong ^a   Jayamani, Elamparithi ^a,b   Kwon, Bumsup ^a   Ausubel, Frederick M ^b   Mylonakis, Eleftherios ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; DAPTOMYCIN; LINEZOLID; METICILLIN; NICLOSAMIDE; OXYCLOZANIDE; POLYMYXIN B; SALICYLANILIDE DERIVATIVE; VANCOMYCIN; VETERINARY DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIOSTASIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG APPROVAL; DRUG REPOSITIONING; ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECIUM; ERYTHROCYTE; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HEPG2 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM EFFECTIVE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SHEEP; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ANIMAL; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; HEP-G2 CELL LINE; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECIUM; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; OVIS ARIES; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTHELMINTICS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECIUM; ERYTHROCYTES; GRAM-NEGATIVE BACTERIA; HEP G2 CELLS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NICLOSAMIDE; OXYCLOZANIDE; SHEEP;

EID: 84928797276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124595     Document Type: Article

References (72)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008; 46 Suppl 5: S344-9.
2. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Seminars in respiratory and critical care medicine. 2003; 24(1):121-34. PMID: 16088531
3. Gottlieb GS, Fowler VG Jr., Kong LK, McClelland RS, Gopal AK, Marr KA, et al. Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. Journal of the American College of Surgeons. 2000; 190(1):50-7. PMID: 10625232
4. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, Pallesen LV, et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2007; 13(3):257-63.
5. Feng Y, Chen CJ, Su LH, Hu S, Yu J, Chiu CH. Evolution and pathogenesis of Staphylococcus aureus: lessons learned from genotyping and comparative genomics. FEMS microbiology reviews. 2008; 32 (1):23-37. PMID: 17983441
6. Lindsay JA. Genomic variation and evolution of Staphylococcus aureus. International journal of medical microbiology: IJMM. 2010; 300(2-3):98-103. doi: 10.1016/j.ijmm.2010.08.004 PMID: 20951087
7. Cuddy SM. Methicillin-resistant Staphylococcus aureus: a new pandemic? Plastic surgical nursing: official journal of the American Society of Plastic and Reconstructive Surgical Nurses. 2008; 28(4):168-9.
8. (CDC) CfDCaP. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Methicillin-Resistant Staphylococcus aureus. 2011 [updated 2012]. Available: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa11.pdf.
9. Silver LL. Challenges of antibacterial discovery. Clinical microbiology reviews. 2011; 24(1):71-109. doi: 10.1128/CMR.00030-10 PMID: 21233508
10. Schaberle TF, Hack IM. Overcoming the current deadlock in antibiotic research. Trends in microbiology. 2014; 22(4):165-7. doi: 10.1016/j.tim.2013.12.007 PMID: 24698433
11. Chopra S, Torres-Ortiz M, Hokama L, Madrid P, Tanga M, Mortelmans K, et al. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii. The Journal of antimicrobial chemotherapy. 2010; 65(12):2598-601. doi: 10.1093/jac/dkq353 PMID: 20861141
12. Carlson-Banning KM, Chou A, Liu Z, Hamill RJ, Song Y, Zechiedrich L. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PloS one. 2013; 8(7):e69646. doi: 10.1371/journal.pone.0069646 PMID: 23936064
13. Weaver AJ Jr., Shepard JB, Wilkinson RA, Watkins RL, Walton SK, Radke AR, et al. Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureus. PloS one. 2014; 9 (5):e97742. doi: 10.1371/journal.pone.0097742 PMID: 24840307
14. Sifri CD, Begun J, Ausubel FM. The worm has turned - microbial virulence modeled in Caenorhabditis elegans. Trends in microbiology. 2005; 13(3):119-27. PMID: 15737730
15. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS pathogens. 2007; 3(7):e101. PMID: 17676994
16. Desalermos A, Tan X, Rajamuthiah R, Arvanitis M, Wang Y, Li D, et al. A Multi-Host Approach for the Systematic Analysis of Virulence Factors in Cryptococcus neoformans. The Journal of infectious diseases. 2014.
17. Rajamuthiah R, Mylonakis E. Effector triggered immunity: Activation of innate immunity in metazoans by bacterial effectors. Virulence. 2014; 5(7). doi: 10.4161/viru.29062 PMID: 25513777
18. Sifri CD, Begun J, Ausubel FM, Calderwood SB. Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infection and immunity. 2003; 71(4):2208-17. PMID: 12654843
19. Irazoqui JE, Troemel ER, Feinbaum RL, Luhachack LG, Cezairliyan BO, Ausubel FM. Distinct pathogenesis and host responses during infection of C. elegans by P. aeruginosa and S. aureus. PLoS pathogens. 2010; 6:e1000982. doi: 10.1371/journal.ppat.1000982 PMID: 20617181
20. Ewbank JJ, Zugasti O. C. elegans: model host and tool for antimicrobial drug discovery. Disease models & mechanisms. 2011; 4(3):300-4.
21. Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, et al. Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant Staphylococcus aureus. PloS one. 2014; 9(2):e89189. doi: 10.1371/journal.pone.0089189 PMID: 24586584
22. Boneca IG, Chiosis G. Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert opinion on therapeutic targets. 2003; 7(3):311-28. PMID: 12783569
23. Macielag MJ, Demers JP, Fraga-Spano SA, Hlasta DJ, Johnson SG, Kanojia RM, et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. Journal of medicinal chemistry. 1998; 41(16):2939-45. PMID: 9685233
24. Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L, et al. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PloS one. 2014; 9 (1):e85887. doi: 10.1371/journal.pone.0085887 PMID: 24416452
25. Tao H, Zhang Y, Zeng X, Shulman GI, Jin S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nature medicine. 2014; 20(11):1263-9. doi: 10.1038/nm.3699 PMID: 25282357
26. Campbell WC. The chemotherapy of parasitic infections. The Journal of parasitology. 1986; 72(1):45-61. PMID: 3519918
27. The selection and use of essential medicines. Report of the WHO Expert Committee, 2002 (including the 12th Model list of essential medicines). 2003 0512-3054 (Print).
28. Roy RM, Sukhla SS. Oxyclozanide-activity against Fasciola gigantica in naturally infected buffalo, cattle, sheep and goats. Tropical animal health and production. 1971; 3(1):26-31. PMID: 5164589
29. Froyd G. Field trials with oxyclozanide. A new liverfluke remedy for sheep and cattle. The British veterinary journal. 1968; 124(3):116-25. PMID: 5689150
30. Cheng TJ, Wu YT, Yang ST, Lo KH, Chen SK, Chen YH, et al. High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase. Bioorganic & medicinal chemistry. 2010; 18(24):8512-29.
31. Kratky M, Vinsova J, Novotna E, Mandikova J, Trejtnar F, Stolakova J. Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates. Molecules. 2013; 18(4):3674-88. doi: 10.3390/molecules18043674 PMID: 23529028
32. Pauk K, Zadrazilova I, Imramovsky A, Vinsova J, Pokorna M, Masarikova M, et al. New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species. Bioorganic & medicinal chemistry. 2013; 21(21):6574-81.
33. Kratky M, Bosze S, Baranyai Z, Szabo I, Stolarikova J, Paraskevopoulos G, et al. Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates. Bioorganic & medicinal chemistry. 2015; 23(4):868-75.
34. Tan MW, Mahajan-Miklos S, Ausubel FM. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(2):715-20. PMID: 9892699
35. Beanan MJ, Strome S. Characterization of a germ-line proliferation mutation in C. elegans. Development. 1992; 116(3):755-66. PMID: 1289064
36. Tanaka-Hino M, Sagasti A, Hisamoto N, Kawasaki M, Nakano S, Ninomiya-Tsuji J, et al. SEK-1 MAPKK mediates Ca2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans. EMBO reports. 2002; 3(1):56-62. PMID: 11751572
37. Jayamani E, Rajamuthiah R, Larkins-Ford J, Fuchs BB, Conery AL, Vilcinskas A, et al. Insect-Derived Cecropins Display Activity against Acinetobacter baumannii in a Whole-Animal High-Throughput Caenorhabditis elegans Model. Antimicrobial agents and chemotherapy. 2015; 59(3):1728-37. doi: 10.1128/AAC.04198-14 PMID: 25583713
38. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics. 2011; 27(8):1179-80. doi: 10.1093/bioinformatics/btr095 PMID: 21349861
39. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, Casadei G, et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS chemical biology. 2009; 4(7):527-33. doi: 10.1021/cb900084v PMID: 19572548
40. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 49(11):1749-55.
41. Haste NM, Hughes CC, Tran DN, Fenical W, Jensen PR, Nizet V, et al. Pharmacological properties of the marine natural product marinopyrrole A against methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2011; 55(7):3305-12. doi: 10.1128/AAC.01211-10 PMID: 21502631
42. Koh JJ, Qiu S, Zou H, Lakshminarayanan R, Li J, Zhou X, et al. Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting. Biochimica et biophysica acta. 2013; 1828(2):834-44. doi: 10.1016/j.bbamem.2012.09.004 PMID: 22982495
43. Isnansetyo A, Kamei Y. MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp. nov. O-BC30(T), against methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2003; 47(2):480-8. PMID: 12543647
44. Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, Persons DA, et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. The Journal of clinical investigation. 2010; 120(2):627-35. doi: 10.1172/JCI39843 PMID: 20093777
45. Kwon B, Kumar P, Lee HK, Zeng L, Walsh K, Fu Q, et al. Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis. Human molecular genetics. 2014; 23(14):3681-94. doi: 10.1093/hmg/ddu077 PMID: 24556217
46. Van Den Bossche H, Verhoeven H, Vanparijs O, Lauwers H, Thienpont D. Closantel, a new antiparasitic hydrogen ionophore [proceedings]. Archives internationales de physiologie et de biochimie. 1979; 87 (4):851-3. PMID: 93944
47. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2010; 31 Suppl 1:S7-10.
48. French GL. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. The Journal of antimicrobial chemotherapy. 2006; 58(6):1107-17. PMID: 17040922
49. Martin RJ. Modes of action of anthelmintic drugs. Veterinary journal. 1997; 154(1):11-34. PMID: 9265850
50. Swan GE. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. Journal of the South African Veterinary Association. 1999; 70(2):61-70. PMID: 10855824
51. Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacology & therapeutics. 1982; 19(2):245-95.
52. Day SR, Moore CM, Kundzins JR, Sifri CD. Community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus virulence toward Caenorhabditis elegans compared. Virulence. 2012; 3(7):576-82. doi: 10.4161/viru.22120 PMID: 23076331
53. Begun J, Sifri CD, Goldman S, Calderwood SB, Ausubel FM. Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infection and immunity. 2005; 73(2):872-7. PMID: 15664928
54. Sifri CD, Baresch-Bernal A, Calderwood SB, von Eiff C. Virulence of Staphylococcus aureus small colony variants in the Caenorhabditis elegans infection model. Infection and immunity. 2006; 74(2):1091-6. PMID: 16428756
55. Wu K, Simor AE, Vearncombe M, McClure JA, Zhang K. A Caenorhabditis elegans host model correlates with invasive disease caused by Staphylococcus aureus recovered during an outbreak in neonatal intensive care. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale / AMMI Canada. 2012; 23(3):130-4.
56. Kirienko NV, Kirienko DR, Larkins-Ford J, Wahlby C, Ruvkun G, Ausubel FM. Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death. Cell host & microbe. 2013; 13(4):406-16.
57. Desalermos A, Muhammed M, Glavis-Bloom J, Mylonakis E. Using C. elegans for antimicrobial drug discovery. Expert opinion on drug discovery. 2011; 6(6):645-52. PMID: 21686092
58. Hu Y, Ellis BL, Yiu YY, Miller MM, Urban JF, Shi LZ, et al. An extensive comparison of the effect of anthelmintic classes on diverse nematodes. PloS one. 2013; 8(7):e70702. doi: 10.1371/journal.pone.0070702 PMID: 23869246
59. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrobial agents and chemotherapy. 1994; 38(8):1732-41. PMID: 7986003
60. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy. 1994; 38(8):1742-52. PMID: 7986004
61. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PloS one. 2011; 6(12):e29290. doi: 10.1371/journal.pone.0029290 PMID: 22195040
62. Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M, et al. Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway. OncoTargets and therapy. 2013; 6:1685-93. doi: 10.2147/OTT.S50065 PMID: 24273411
63. Hilliard JJ, Goldschmidt RM, Licata L, Baum EZ, Bush K. Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrobial agents and chemotherapy. 1999; 43(7):1693-9. PMID: 10390224
64. Zhu ZW, Shi L, Ruan XM, Yang Y, Li HQ, Xu SP, et al. Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. Journal of enzyme inhibition and medicinal chemistry. 2011; 26(1):37-45. doi: 10.3109/14756361003671060 PMID: 20583855
65. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, et al. A simple model host for identifying Gram-positive virulence factors. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(19):10892-7. PMID: 11535834
66. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001; 357(9264):1225-40. PMID: 11418146
67. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science. 1995; 268(5219):1899-902. PMID: 7604262
68. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. Journal of bacteriology. 2008; 190(1):300-10. PMID: 17951380
69. Nair D, Memmi G, Hernandez D, Bard J, Beaume M, Gill S, et al. Whole-genome sequencing of Staphylococcus aureus strain RN4220, a key laboratory strain used in virulence research, identifies mutations that affect not only virulence factors but also the fitness of the strain. Journal of bacteriology. 2011; 193 (9):2332-5. doi: 10.1128/JB.00027-11 PMID: 21378186
70. Novick RP, Ross HF, Projan SJ, Kornblum J, Kreiswirth B, Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. The EMBO journal. 1993; 12(10):3967-75. PMID: 7691599
71. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. Journal of clinical microbiology. 2003; 41(11):5113-20. PMID: 14605147
72. Mack D, Nedelmann M, Krokotsch A, Schwarzkopf A, Heesemann J, Laufs R. Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin. Infection and immunity. 1994; 62(8):3244-53. PMID: 8039894